The effect of safranal in prevention of cognitive decline in intracerebroventricular streptozotocin model of Alzheimer’s disease in the rat

Shahram Jalalzadeh | Ensie Azadi Ahmadabadi | Farzane Fereidoni | Zahra Kiasalari Reineh | Mehrdad Roghani

---

URL :   http://research.shahed.ac.ir/WSR/WebPages/Report/PaperView.aspx?PaperID=137482
Date :  2019/10/30
Publish in :    24 امين کنگره ملي و سومين کنگره بين المللي فيزيولوژي و فارماکولوژي ايران


Keywords :Streptozotocin, Safranal, Cognition

Abstract :

---

Background and Objective: Cognitive decline is associated with Alzheimers disease (AD) that is a chronic and progressive syndrome with a neurodegenerative nature that finally leads to irreversible deterioration of neurons. In this study, we evaluated whether safranal could prevent cognitive decline in intracerebroventricular streptozotocin (STZ)-induced model of AD in the rat. Materials and Methods: Male rats (n=32) were assigned to four groups, i.e., Sham, lesion (receiving intracerebroventricular STZ bilaterally at a dose of 3 mg), and two lesion groups receiving safranal p.o. at doses of 10 or 50 mg/kg in addition to intracerebroventricular STZ. Finally, performance of rats in passive avoidance and Ymaze tests was assessed to explore cognition. Results: Our obtained data indicated that intracerebroventricular STZ is associated with significant dysfunction in Y-maze and passive avoidance tasks and administration of safranal to intracerebroventricular STZ group at a dose of 50 mg/kg significantly improves performance of animals in these tests. Conclusion: Collectively, safranal at a dose of 50 mg/kg could significantly attenuate cognitive dysfunction induced by intracerebroventricular injection of STZ in the rat.